Clinical Trial Update: INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY

View source ↗

Summary

The document announces an expanded-access program for treating sarcopenic obesity sponsored by Immunis, Inc., and notes that the program is temporarily not avai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Sarcopenia

Snippet

Sponsor: Immunis, Inc. | Conditions: Sarcopenia, Obesity and Obesity-related Medical Conditions | Status: TEMPORARILY_NOT_AVAILABLE